...
首页> 外文期刊>Journal of the American Society for Mass Spectrometry >Fourier transform-ion cyclotron resonance mass spectrometric resolution, identification, and screening of non-covalent complexes of Hck Src homology 2 domain receptor and ligands from a 324-member peptide combinatorial library
【24h】

Fourier transform-ion cyclotron resonance mass spectrometric resolution, identification, and screening of non-covalent complexes of Hck Src homology 2 domain receptor and ligands from a 324-member peptide combinatorial library

机译:傅里叶变换离子回旋共振质谱解析,鉴定和筛选Hck Src同源2域受体和来自324个成员的肽组合库的配体的非共价复合物

获取原文
获取原文并翻译 | 示例

摘要

The preferred ligands for the Hck Src homology 2 domain among a combinatorial library containing 324 different peptides were determined in a single experiment involving Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry (MS), electrospray ionization (ESI), stored-waveform inverse Fourier transformation (SWIFT), and infrared multiphoton laser disassociation (IRMPD). These were compared with the results obtained by conventional screening of the peptide library in solution using affinity chromatography. The results reported here show that by combining ESI, FT-ICR MS, SWIFT, and IRMPD, ligands likely to bind under physiological conditions are rapidly and efficiently identified, even from complex library mixtures. In the gas phase some discrimination against hydrophobic ligands could be observed. However, the illustrated feasibility of identifying high affinity ligand via gas-phase screening of complex library mixtures should lead to broad applications in the development of ligands for proteins with interesting biological activity, the first step that must be taken to develop a therapeutic agent. [References: 34]
机译:在单个实验中确定了包含324种不同肽的组合文库中Hck Src同源2域的首选配体,该实验涉及傅立叶变换离子回旋共振(FT-ICR)质谱(MS),电喷雾电离(ESI),存储波形逆傅立叶变换(SWIFT)和红外多光子激光解离(IRMPD)。将这些与通过使用亲和层析在溶液中常规筛选肽文库获得的结果进行比较。此处报道的结果表明,通过结合ESI,FT-ICR MS,SWIFT和IRMPD,即使在复杂的文库混合物中,也可以快速,有效地识别在生理条件下可能结合的配体。在气相中,可以观察到对疏水配体的一些区别。然而,通过气相筛选复杂的文库混合物鉴定高亲和力配体所说明的可行性,应在开发具有令人感兴趣的生物学活性的蛋白质的配体中广泛应用,这是开发治疗剂必须采取的第一步。 [参考:34]

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号